Article
Biochemistry & Molecular Biology
Upasana Ray, Prabhu Thirusangu, Ling Jin, Yinan Xiao, Christopher L. Pathoulas, Julie Staub, Courtney L. Erskine, Keith Dredge, Edward Hammond, Matthew S. Block, Scott H. Kaufmann, Jamie N. Bakkum-Gamez, Viji Shridhar
Summary: PG545 is a highly sulfated small molecule that inhibits heparanase and disrupts signaling mediated by heparan-binding-growth factors. It induces DNA damage in ovarian cancer cells by inducing DNA single- and double-strand breaks, reducing RAD51 expression, and inhibiting homologous recombination repair. PG545 also synergizes with PARP inhibitors in ovarian cancer cell lines and primary cultures of patient-derived ascites samples. In addition, it shows increased antitumor effects and survival in xenograft and immunocompetent syngeneic OC models. Targeting DEK-HSPG interactions through PG545 may inhibit DNA repair and sensitize cells to PARP inhibitors.
Article
Oncology
Rebecca S. Kristeleit, Yvette Drew, Amit M. Oza, Susan M. Domchek, Susana Banerjee, Rosalind M. Glasspool, Judith Balmana, Lee-may Chen, Manish R. Patel, Howard A. Burris, Tamar Safra, Jennifer Borrow, Kevin K. Lin, Sandra Goble, Lara Maloney, Ronnie Shapira-Frommer
Summary: This study evaluated the efficacy and safety of oral rucaparib monotherapy in heavily pretreated patients with ovarian cancer. The results showed that rucaparib had robust antitumour activity and a good safety profile in patients who had received multiple prior chemotherapies.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Elizabeth M. Swisher, Rebecca S. Kristeleit, Amit M. Oza, Anna Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Howard A. Burris, Carol Aghajanian, David M. O'Malley, Alexandra Leary, Stephen Welch, Diane Provencher, Geoffrey Shapiro, Lee-May Chen, Ronnie Shapira-Frommer, Scott H. Kaufmann, Sandra Goble, Lara Maloney, Tanya Kwan, Kevin K. Lin, Iain A. McNeish
Summary: The study found that a significant proportion of HGOC patients who responded to the PARP inhibitor rucaparib had long-term responses, with most of them harboring BRCA1 or BRCA2 mutations, particularly BRCA structural variants. Patients with BRCA structural variants had significantly longer duration of response compared to those with other mutation types, indicating a relationship between this specific mutation type and treatment response. Additionally, patients with high genome-wide LOH without BRCA mutations also exhibited long-term responses, suggesting potential molecular characteristics associated with treatment outcomes.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Adarsh Ghosh, Ensar Yekeler, Deepa Dalal, Alexandria Holroyd, Lisa States
Summary: The study aimed to determine the role of ADC histogram analysis in identifying MYCN-amplification status in neuroblastomas. The results showed that ADC histogram analysis can differentiate between tumors with and without MYCN amplification, and can help identify areas for targeted biopsies or predict subtypes of high-risk tumors before biopsy results are available.
EUROPEAN RADIOLOGY
(2022)
Article
Medicine, Research & Experimental
Gokul Sudhakaran, Sarvesh Ramesh Babu, Hridai Mahendra, Jesu Arockiaraj
Summary: Polycystic ovarian syndrome (PCOS) is caused by hormonal imbalance and hyperandrogenism. Animal models are commonly used to study PCOS due to their similarity to human PCOS, but the pathogenesis of PCOS is still unclear. Novel drugs from different sources are being screened as therapeutic strategies for PCOS and its symptoms. Simplified cell line in-vitro models can be used to preliminarily screen the bioactivity of various drugs. This review focuses on different cell line models for PCOS and its complications, allowing for preliminary drug screening before moving to higher animal models.
Article
Multidisciplinary Sciences
Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O'Malley, Alexandra Leary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca S. Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin K. Lin, Iain A. McNeish
Summary: RAD51C, RAD51D mutations, and high-level BRCA1 promoter methylation can predict response to the PARP inhibitor rucaparib, while BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi.
NATURE COMMUNICATIONS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Robert W. Regenhardt, R. Gilberto Gonzalez, Julian He, Michael H. Lev, Aneesh B. Singhal
Summary: The study aims to evaluate whether symmetric collaterals at CTA can help identify patients with low ischemic core growth rate (IGR) and small 24-hour ischemic core volume in patients with large vessel occlusion (LVO) not treated with reperfusion therapies. The results indicate that symmetric collaterals are highly specific for low IGR and small ischemic core volume.
Article
Biochemistry & Molecular Biology
Mohamad Haider, Shilpa Sharma, Ashish Kumar Agrahari, Madhu Dikshit, Dharam Pal Pathak, Shailendra Asthana
Summary: This study explores the development of ASK1 inhibitors and generates diverse chemical scaffolds using structural pharmacophore and enumeration strategy. A large number of candidate compounds were evaluated through virtual screening, and a lead candidate, S3C-1-D424, was identified based on docking and MM-GBSA scores. Comparative molecular dynamics simulations and pharmacokinetics profiling provide evidence for the suitability of S3C-1-D424 as a potential ASK1 inhibitor for further exploration.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Multidisciplinary Sciences
Jinfeng Bai, Zeying Li, Junlong Guo, Fuxin Gao, Hui Zhou, Weijie Zhao, Xiang Ma
Summary: This study aimed to develop a predictive model to select MBC patients who would benefit most from surgery. Data from SEER database and Yunnan Cancer Hospital were used to analyze the baseline characteristics and survival outcomes. A nomogram was established to predict the likelihood of survival benefit from primary tumor resection, which showed strong consistency between actual and predicted survival.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Bradley J. Monk, Christine Parkinson, Myong Cheol Lim, David M. O'Malley, Ana Oaknin, Michelle K. Wilson, Robert L. Coleman, Domenica Lorusso, Paul Bessette, Sharad Ghamande, Athina Christopoulou, Diane Provencher, Emily Prendergast, Fuat Demirkiran, Olga Mikheeva, Oladapo Yeku, Anita Chudecka-Glaz, Michael Schenker, Ramey D. Littell, Tamar Safra, Hung-Hsueh Chou, Mark A. Morgan, Vit Drochytek, Joyce N. Barlin, Toon Van Gorp, Fred Ueland, Gabriel Lindahl, Charles Anderson, Dearbhaile C. Collins, Kathleen Moore, Frederik Marme, Shannon N. Westin, Iain A. McNeish, Danny Shih, Kevin K. Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca S. Kristeleit
Summary: This study evaluates the efficacy of rucaparib as a first-line maintenance treatment in ovarian cancer patients, showing significant benefits of rucaparib compared to placebo in patients with and without HRD.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Reproductive Biology
B. G. Alves, K. A. Alves, K. A. Hyde, F. L. N. Aguiar, S. S. Souza, F. A. S. Brandao, E. C. Garcia, Y. Pinto, M. O. Gastal, J. R. Figueiredo, D. I. A. Teixeira, E. L. Gastal
Summary: The study examined the efficacy of intramuscular and subvulvar mucosa heterotopic autotransplantation sites for maintaining the survivability of ovarian grafts. The results showed similar macroscopic scores between the two transplantation sites 7 days post-OTT, with a lower percentage of morphologically normal follicles found in the subvulvar mucosa site compared to the fresh control group and intramuscular site.
Article
Psychiatry
Phoebe Barnett, Rob Saunders, Joshua E. J. Buckman, Ana Cardoso, Mirko Cirkovic, Judy Leibowitz, Nicole Main, Syed A. Naqvi, Satwant Singh, Joshua Stott, Lila Varsani, Jon Wheatly, Stephen Pilling
Summary: This study compared the psychological treatment outcomes between university students and young adults in employment, revealing that students were less likely to recover and improve at the end of treatment, suggesting the need for additional support and treatment adaptations that account for student-specific stressors.
COMPREHENSIVE PSYCHIATRY
(2022)
Article
Engineering, Environmental
Mengxi Yu, Hans Pasman, Madhav Erraguntla, Noor Quddus, Costas Kravaris
Summary: The study discusses the challenges of identifying, observing and responding to weak signals in complex systems, and proposes an effective framework to address these issues. By utilizing various classification models, the relevance of weak signals can be accurately evaluated and corresponding measures can be taken to prevent accidents.
PROCESS SAFETY AND ENVIRONMENTAL PROTECTION
(2022)
Article
Biochemistry & Molecular Biology
Yoon-Young Kim, Kwang-Soo Kim, Yong-Jin Kim, Sung-Woo Kim, Hoon Kim, Seung-Yup Ku
Summary: The study extensively investigated premature ovarian insufficiency in females, identifying differentially expressed genes through RNA sequencing and highlighting the crucial role of miRNAs in regulation, especially in different stages of ovarian development impacting key genes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cell Biology
Xiushen Li, Weizheng Liang, Huanyi Zhao, Zheng Jin, Guoqi Shi, Wanhua Xie, Hao Wang, Xueqing Wu
Summary: This study analyzed the immune infiltration landscape in ovarian cancer, constructing an ICI score and prognostic model based on immune-related genes to predict patient outcomes and identify potential candidates for immunotherapy. Clustering analysis of ICI genes revealed certain patient clusters with better prognosis and specific immune cell proportions in the tumor microenvironment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Eun-Young Kang, Ashley Weir, Nicola S. Meagher, Kyo Farrington, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Adelyn Bolithon, Gordana Popovic, Betty Leung, Katrina Tang, Neil Lambie, Joshua Millstein, Jennifer Alsop, Michael S. Anglesio, Beyhan Ataseven, Ellen Barlow, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Hans Boesmueller, Jessica Boros, Alison H. Brand, Angela Brooks-Wilson, Sara Y. Brucker, Michael E. Carney, Yovanni Casablanca, Alicia Cazorla-Jimenez, Paul A. Cohen, Thomas P. Conrads, Linda S. Cook, Penny Coulson, Madeleine Courtney-Brooks, Daniel W. Cramer, Philip Crowe, Julie M. Cunningham, Cezary Cybulski, Kathleen M. Darcy, Mona A. El-Bahrawy, Esther Elishaev, Ramona Erber, Rhonda Farrell, Sian Fereday, Anna Fischer, Maria J. Garcia, Simon A. Gayther, Aleksandra Gentry-Maharaj, C. Blake Gilks, Marcel Grube, Paul R. Harnett, Shariska Petersen Harrington, Philipp Harter, Arndt Hartmann, Jonathan L. Hecht, Sebastian Heikaus, Alexander Hein, Florian Heitz, Joy Hendley, Brenda Y. Hernandez, Susanna Hernando Polo, Sabine Heublein, Akira Hirasawa, Estrid Hogdall, Claus K. Hogdall, Hugo M. Horlings, David G. Huntsman, Tomasz Huzarski, Andrea Jewell, Mercedes Jimenez-Linan, Michael E. Jones, Scott H. Kaufmann, Catherine J. Kennedy, Dineo Khabele, Felix K. F. Kommoss, Roy F. P. M. Kruitwagen, Diether Lambrechts, Nhu D. Le, Marcin Lener, Jenny Lester, Yee Leung, Anna Linder, Liselore Loverix, Jan Lubinski, Rashna Madan, G. Larry Maxwell, Francesmary Modugno, Susan L. Neuhausen, Alexander Olawaiye, Siel Olbrecht, Sandra Orsulic, Jose Palacios, Celeste Leigh Pearce, Malcolm C. Pike, Carmel M. Quinn, Ganendra Raj Mohan, Cristina Rodriguez-Antona, Matthias Ruebner, Andy Ryan, Stuart G. Salfinger, Naoko Sasamoto, Joellen M. Schildkraut, Minouk J. Schoemaker, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Naveena Singh, Gabe S. Sonke, Linda Steele, Colin J. R. Stewart, Karin Sundfeldt, Anthony J. Swerdlow, Aline Talhouk, Adeline Tan, Sarah E. Taylor, Kathryn L. Terry, Aleksandra Toloczko, Nadia Traficante, Koen K. Van de Vijver, Maaike A. van der Aa, Toon Van Gorp, Els Van Nieuwenhuysen, Lilian Van-Wagensveld, Ignace Vergote, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Anna H. Wu, Javier Benitez, Andrew Berchuck, Francisco J. Candido Dos Reis, Anna DeFazio, Peter A. Fasching, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, Beth Y. Karlan, Stefan Kommoss, Usha Menon, Hans-Peter Sinn, Annette Staebler, James D. Brenton, David D. Bowtell, Paul D. P. Pharoah, Susan J. Ramus, Martin Kobel
Summary: This study validates that high-level amplification of CCNE1 is associated with shorter survival in tubo-ovarian high-grade serous carcinoma (HGSC), supporting its use as a prognostic biomarker in this disease.
Article
Oncology
Minh Tung Phung, Penelope M. Webb, Anna DeFazio, Sian Fereday, Alice W. Lee, David D. L. Bowtell, Peter A. Fasching, Ellen L. Goode, Marc T. Goodman, Beth Y. Karlan, Jenny Lester, Keitaro Matsuo, Francesmary Modugno, James D. Brenton, Toon Van Gorp, Paul D. P. Pharoah, Joellen M. Schildkraut, Karen McLean, Rafael Meza, Bhramar Mukherjee, Jean Richardson, Bronwyn Grout, Anne Chase, Cindy McKinnon Deurloo, Kathryn L. Terry, Gillian E. Hanley, Malcolm C. Pike, Andrew Berchuck, Susan J. Ramus, Celeste Leigh Pearce, Ovarian Canc Assoc Consortium
Summary: This study analyzed the association between 12 lifestyle and personal exposures and having residual disease after surgery in patients with high-grade serous ovarian cancer (HGSC). The use of menopausal estrogen-only therapy (ET) was associated with a lower likelihood of having macroscopic residual disease, while parous women who did not breastfeed also had a lower likelihood of residual disease. These factors could potentially be included in risk stratification models for HGSC patients.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Nicola S. Meagher, Phineas Hamilton, Katy Milne, Shelby Thornton, Bronwyn Harris, Ashley Weir, Jennifer Alsop, Christiani Bisinoto, James D. Brenton, Angela Brooks-Wilsoni, Derek S. Chiu, Kara L. Cushing-Haugen, Sian Fereday, Dale W. Garsed, Simon A. Gayther, Aleksandra Gentry-Maharaj, Blake Gilks, Mercedes Jimenez-Linan, Catherine J. Kennedy, Nhu D. Le, Anna M. Piskorz, Marjorie J. Riggan, Mitul Shah, Naveena Singh, Aline Talhoukj, Martin Widschwendter, David D. L. Bowtell, Francisco J. Candido dos Reis, Linda S. Cook, Renee T. Fortner, Maria J. Garcia, Holly R. Harris, David G. Huntsman, Anthony N. Karnezis, Martin Kobel, Usha Menon, Paul D. P. Pharoah, Jennifer A. Doherty, Michael S. Anglesioj, Malcolm C. Pike, Celeste Leigh Pearce, Michael L. Friedlander, Anna DeFazio, Brad H. Nelson, Susan J. Ramus
Summary: This study conducted immunohistochemistry and immunofluorescence on 126 patients with mucinous ovarian carcinoma (MOC) and found that MOCs are mainly characterized by high densities of immune suppressor cells in the tumor epithelium, suggesting limited response to current immunotherapies.
GYNECOLOGIC ONCOLOGY
(2023)
Review
Immunology
Funingana Ionut-Gabriel, Jacob S. Bedia, Ying-Wen Huang, Antonio Delgado Gonzalez, Kenyi Donoso, Veronica D. Gonzalez, James D. Brenton, Alan Ashworth, Wendy J. Fantl
Summary: High-grade serous ovarian cancer (HGSOC) is a challenging gynecological malignancy due to its advanced stage diagnosis, diverse carboplatin resistance mechanisms, and lack of response to immunotherapy. Multiplex single-cell proteomic technologies could provide insights into the functional interplay between cell autonomous responses to carboplatin and the HGSOC immune tumor microenvironment. This review suggests that the incorporation of multiplex single-cell proteomic technologies into biomarker development, along with genomics and radiomics, could improve clinical care for HGSOC patients.
SEMINARS IN IMMUNOPATHOLOGY
(2023)
Article
Oncology
Sudha Sundar, Andy Nordin, Jo Morrison, Nick Wood, Sadaf Ghaem-Maghami, Jo Nieto, Andrew Phillips, John Butler, Kevin Burton, Rob Gornall, Stephen Dobbs, Rosalind Glasspool, Richard Peevor, Jonathan Ledermann, Iain McNeish, Nithya Ratnavelu, Tim Duncan, Jonathan Frost, Kenneth Lim, Agnieszka Michael, Elly Brockbank, Ketankumar Gajjar, Alexandra Taylor, Rebecca Bowen, Adrian Andreou, Raji Ganesan, Shibani Nicum, Richard Edmondson, Richard Clayton, Janos Balega, Phil Rolland, Hilary Maxwell, Christina Fotopoulou
Summary: Ovarian cancer survival in the UK is lower than in comparable countries. A study showed that 1 in 4 women with advanced stage ovarian cancer do not receive any treatment, and only 51% receive surgery and chemotherapy in England. There is also significant variation in treatment rates across different regions. To improve outcomes, the British Gynaecological Cancer Society has developed quality performance indicators that can be evaluated using routine data.
Article
Oncology
Denise G. O'Mahony, Susan J. Ramus, Melissa C. Southey, Nicola S. Meagher, Andreas Hadjisavvas, Esther M. John, Ute Hamann, Evgeny N. Imyanitov, Irene L. Andrulis, Priyanka Sharma, Mary B. Daly, Christopher R. Hake, Jeffrey N. Weitzel, Anna Jakubowska, Andrew K. Godwin, Adalgeir Arason, Anita Bane, Jacques Simard, Penny Soucy, Maria A. Caligo, Phuong L. Mai, Kathleen B. M. Claes, Manuel R. Teixeira, Wendy K. Chung, Conxi Lazaro, Peter J. Hulick, Amanda E. Toland, Inge Sokilde Pedersen, Susan L. Neuhausen, Ana Vega, Miguel de la Hoya, Heli Nevanlinna, Mallika Dhawan, Valentina Zampiga, Rita Danesi, Liliana Varesco, Viviana Gismondi, Valerio Gaetano Vellone, Paul A. James, Ramunas Janavicius, Liene Nikitina-Zake, Finn Cilius Nielsen, Thomas van Overeem Hansen, Tanja Pejovic, Ake Borg, Johanna Rantala, Kenneth Offit, Marco Montagna, Katherine L. Nathanson, Susan M. Domchek, Ana Osorio, Maria J. Garcia, Beth Y. Karlan, Anna De Fazio, David Bowtell, Lesley McGuffog, Goska Leslie, Michael T. Parsons, Thilo Doerk, Lisa-Marie Speith, Elizabeth Santana dos Santos, Alexandre Andre B. A. da Costa, Paolo Radice, Paolo Peterlongo, Laura Papi, Christoph Engel, Eric Hahnen, Rita K. Schmutzler, Barbara Wappenschmidt, Douglas F. Easton, Marc Tischkowitz, Christian F. Singer, Yen Yen Tan, Alice S. Whittemore, Weiva Sieh, James D. Brenton, Drakoulis Yannoukakos, Florentia Fostira, Irene Konstantopoulou, Jana Soukupova, Michal Vocka, Georgia Chenevix-Trench, Paul D. P. Pharoah, Antonis C. Antoniou, David E. Goldgar, Amanda B. Spurdle, Kyriaki Michailidou, Marian J. E. Mourits, Fabienne Lesueur
Summary: This study assessed the utility of ovarian tumour characteristics as predictors of BRCA1 and BRCA2 variant pathogenicity and provided evidence for improved classification and clinical management of carriers.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Robert D. Morgan, Andrew R. Clamp, Bethany M. Barnes, Kirsten Timms, Helene Schlecht, Laura Yarram-Smith, Yvonne Wallis, Mikel Valganon-Petrizan, Suzanne MacMahon, Rhian White, Sian Morgan, Sarah McKenna, Emma Hudson, Laura Tookman, Angela George, Ranjit Manchanda, Sudha S. Sundar, Shibani Nicum, James D. Brenton, Rebecca S. Kristeleit, Susana Banerjee, Iain A. McNeish, Jonathan A. Ledermann, Stephen S. Taylor, D. Gareth R. Evans, Gordon C. Jayson
Summary: This study reports data from the first year of routine homologous recombination deficiency testing in the NHS in England, Wales, and Northern Ireland, demonstrating the significant survival benefits of olaparib plus bevacizumab maintenance therapy in women with newly diagnosed, advanced, high-grade ovarian cancer.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Biochemistry & Molecular Biology
David B. Morse, Aleksandra M. Michalowski, Michele Ceribelli, Joachim De Jonghe, Maria Vias, Deanna Riley, Theresa Davies-Hill, Ty Voss, Stefania Pittaluga, Christoph Muus, Jiamin Liu, Samantha Boyle, David A. Weitz, James D. Brenton, Jason D. Buenrostro, Tuomas P. J. Knowles, Craig J. Thomas
Summary: Single-cell RNA sequencing (scRNA-seq) is used to describe cell states, but the spatial arrangement of these states in tissues is challenging. Segmentation by exogenous perfusion (SEEP) is a method that links surface proximity and environment accessibility to transcriptional identity within 3D disease models. Using SEEP, analysis of ovarian cancer models reveals the relationship between cell state and position, and shows how microenvironments influence individual cell identities.
Article
Medicine, General & Internal
Olivier Colomban, Elizabeth M. Swisher, Rebecca Kristeleit, Iain McNeish, Ronnie Shapira-Frommer, Sandra Goble, Kevin K. Lin, Lara Maloney, Gilles Freyer, Benoit You
Summary: Mathematical modeling of early CA-125 kinetics can be used as an indicator of rucaparib efficacy in recurrent ovarian carcinoma patients. The KELIM-PARP score is associated with treatment response and progression-free survival. This study suggests the potential use of this strategy in selecting patients for PARPi-based treatment regimens.
Article
Oncology
Maria Delgado-Ortet, Marika A. V. Reinius, Cathal McCague, Vlad Bura, Ramona Woitek, Leonardo Rundo, Andrew B. Gill, Marcel Gehrung, Stephan Ursprung, Helen Bolton, Krishnayan Haldar, Pubudu Pathiraja, James D. Brenton, Mireia Crispin-Ortuzar, Mercedes Jimenez-Linan, Lorena Escudero Sanchez, Evis Sala
Summary: In this study, a research pathway and automated computational pipeline were developed to create lesion-specific 3D-printed moulds based on preoperative imaging, allowing for detailed spatial correlation between imaging and tissue-derived data. This method can guide comprehensive multi-sampling of various pelvic tumors.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
A. M. Mahedi Hasan, Paolo Cremaschi, Daniel Wetterskog, Anuradha Jayaram, Stephen Q. Wong, Scott Williams, Anupama Pasam, Anna Trigos, Blanca Trujillo, Emily Grist, Stefanie Friedrich, Osvaldas Vainauskas, Marina Parry, Mazlina Ismail, Wout Devlies, Anna Wingate, Mark Linch, Cristina Naceur-Lombardelli, Charles Swanton, Mariam Jamal-Hanjani, Stefano Lise, Shahneen Sandhu, Gerhardt Attard
Summary: By analyzing the genomic complexity of AR across lethal metastases from 10 prostate cancer patients, the study finds diverse and patient-specific AR gene alterations, as well as independent acquisition of related genomic changes within an individual and the existence of AR-neutral clones. The study also confirms a common clone of origin across metastases and identifies clusters of metastases with diverged autosomal copy number alterations. These findings provide insights into the heterogeneity and evolution of AR alterations in metastatic prostate cancer.
NATURE COMMUNICATIONS
(2023)
Article
Multidisciplinary Sciences
Philip Smith, Thomas Bradley, Lena Morrill Gavarro, Teodora Goranova, Darren P. Ennis, Hasan B. Mirza, Dilrini De Silva, Anna M. Piskorz, Carolyn Sauer, Sarwah Al-Khalidi, Ionat-Gabriel Funingana, Marika A. V. Reinius, Gaia Giannone, Liz-Anne Lewsley, Jamie Stobo, John McQueen, Gareth Bryson, Matthew Eldridge, R. M. Glasspool, C. Gourley, R. Kennedy, G. Hall, R. Edmondson, A. Clamp, S. Sundar, A. Walter, M. Hall, H. Gabra, C. Fotopoulou, E. Brockbank, A. Montes, M. Lockley, Geoff Macintyre, Florian Markowetz, James D. Brenton, Iain A. McNeish
Summary: Treatment resistance is common in ovarian high grade serous carcinoma, often leading to relapse. Here, the authors leverage shallow whole genome and panel sequencing of 276 patients with available diagnostic and relapse samples and show high concordance of copy number and mutation status.
NATURE COMMUNICATIONS
(2023)
Letter
Oncology
Gaia Giannone, Iain A. Mcneish, Susana Banerjee
Review
Oncology
Chandler Bray, Cristina Balcells, Iain A. Mcneish, Hector C. Keun
Summary: This article discusses the rationale and methods for targeting the MAT2A/PRMT5 axis in cancer therapy. While inhibitors targeting PRMT5 or MAT2A have shown promise in oncology, their clinical development has been challenging, highlighting the need for further understanding of downstream mediators and addressing related challenges.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
